DOI: 10.4244/EIJV8I4A63

Lettres de noblesse: the three milestones

Patrick W. Serruys, Editor-in-Chief

Dear colleagues,

Although the Impact Factor (IF) was created in 1955 for a world without faxes, computers, smartphones or the Internet, it is still recognised today as a critical and very academic parameter of scientific assessment. In the life of a scientific journal, the first milestone is to be recognised and indexed by PubMed, the second is to have your official IF determined.

While we were aware of its importance, we remained cautious about requesting our IF immediately, choosing to follow the unusual strategy of waiting in order to benefit from the extra exposure and momentum gained after our early years of existence. Like this we hoped to achieve a higher first IF. The result of this strategy has paid off been better than we expected –we have now received our IF and it is very close to 3.3– this has put us in an excellent position with respect to our “so-called” long-term competitors.

We have now arrived at the end of the beginning for EuroIntervention and while there is still a long way to go before we can aspire to join the ranks of the European Heart Journal or the other, US based, cardiology journals, we have begun the long climb, we have received our “lettres de noblesses”. At the present, what is still unknown, is whether journals that deal with percutaneous interventions remain in the 2-5 IF range or progress beyond this level.

Still, while we are proud of our hard won IF, we would like to reiterate our wish for an evolution – an upgrade or update of the IF itself. It is clear that in today’s world of eblasts, iPads and instant downloads, not to mention Facebook and Twitter, that 57 years after its inception, the IF should be rejuvenated and readjusted to better reflect our changing world.

The third milestone

If you have been following us these last years you know we will not take the time to rest on our laurels. We have achieved our first two milestones –PubMed and the Impact Factor– now we have given ourselves the challenge of a third “défi”… to be in the top 25% of Cardiology Journals published internationally. We are now firmly in the top 50% (the 2nd quartile), but the reality today within the academic world requires that you submit papers only to journals within the top 25% (1st quartile) as funding will become increasingly linked to this quartile. To see where we are today requires a simple calculation. There are 117 journals in our field, EuroIntervention is now number 36 and 25% of 117 is approximately number 30. For EuroIntervention to enter the 1st quartile we would need an IF of at least 3.7. The challenge today, our 3rd milestone, is that we try to make the jump to an IF of 4.0 or above.

Over the next few months we will be analysing this and sharing with you our ideas of how striving after a certain excellence, and anticipating the needs of our community can only work to benefit us all, pushing the Journal to new heights with an increasing IF, and offering a European and international forum of quality for our latest research and our speciality.

Finally, on a personal note, I would like to sincerely thank the authors who submitted their articles and bestowed their trust on, what was before, a non -IF journal, and to the many reviewers who gave us their time and effort without any tangible reward except the desire to further the work of our European science. On behalf of our team, we look forward to carrying on the work with both authors and reviewers, which now will undoubtedly entail even more submissions and review work. Our future work is cut out for us; how we succeed depends on both you and ourselves, but only the numbers will tell if we reach our third milestone.

Volume 8 Number 4
Aug 24, 2012
Volume 8 Number 4
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV12I4A72 Jul 20, 2016
The Journal Citation Reports® Impact Factor: annual results 2016
Cummins P and Serruys PW
free

10.4244/EIJV10I5A93 Sep 28, 2014
Impact Factor 2014: hoping this will be more the rule than the exception
Cummins P and Serruys PW
free

10.4244/EIJV13I13A239 Jan 19, 2018
Beyond the impact factor: may we have your attention, please?
Capodanno D
free

10.4244/EIJV15I9A135 Oct 4, 2019
The EuroIntervention health check 2019
Mylotte D et al
free

10.4244/EIJV8I5A81 Sep 28, 2012
The “Big Brother”
Serruys PW
free

10.4244/EIJV8I1A1 May 15, 2012
Pockets full of good news in the Age of Reason
Serruys PW
free

10.4244/EIJV7I5A85 Sep 30, 2011
Fast tracking to the future with EEP
Serruys PW
free
Trending articles
151.43

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
55.9

Clinical research

10.4244/EIJ-D-22-00621 Feb 20, 2023
Long-term changes in coronary physiology after aortic valve replacement
Sabbah M et al
free
54.9

Expert review

10.4244/EIJ-D-21-01010 Jun 24, 2022
Device-related thrombus following left atrial appendage occlusion
Simard T et al
free
43.75

Clinical Research

10.4244/EIJ-D-21-01091 Aug 5, 2022
Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study
Medranda G et al
free
39.95

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved